Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
Wall Street Analyst Weigh In
MASI has been the topic of a number of research analyst reports. Stifel Nicolaus cut their target price on Masimo from $175.00 to $150.00 in a research report on Wednesday, May 4th. Piper Sandler boosted their target price on Masimo from $130.00 to $135.00 and gave the company a "neutral" rating in a research report on Wednesday, August 10th. StockNews.com lowered Masimo from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th. Finally, Needham & Company LLC upped their price objective on Masimo from $163.00 to $179.00 and gave the stock a "buy" rating in a research report on Wednesday, August 10th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $183.80.
Masimo Stock Up 3.5 %
NASDAQ:MASI traded up $5.40 during trading hours on Monday, hitting $159.77. The company's stock had a trading volume of 2,247,427 shares, compared to its average volume of 925,814. The stock has a market capitalization of $8.87 billion, a P/E ratio of 46.50 and a beta of 0.98. The stock has a fifty day moving average of $137.78 and a 200-day moving average of $147.71. The company has a current ratio of 2.10, a quick ratio of 1.28 and a debt-to-equity ratio of 0.77. Masimo has a 52-week low of $112.07 and a 52-week high of $305.21.
Masimo (NASDAQ:MASI - Get Rating) last posted its earnings results on Tuesday, August 9th. The medical equipment provider reported $1.35 EPS for the quarter, beating the consensus estimate of $1.19 by $0.16. Masimo had a return on equity of 17.39% and a net margin of 12.68%. The firm had revenue of $565.30 million for the quarter, compared to analyst estimates of $540.56 million. During the same quarter in the prior year, the company posted $0.94 earnings per share. Masimo's revenue for the quarter was up 87.9% compared to the same quarter last year. On average, equities analysts forecast that Masimo will post 4.47 earnings per share for the current year.